Get the Stockscreener App
58.20
0.00%
0.00
After Hours:
57.50
-0.70
-1.20%
Scholar Rock Holding Corp stock is traded at $58.20, with a volume of 1.22M.
It is up +0.00% in the last 24 hours and up +22.09% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$58.20
Open:
$56.8
24h Volume:
1.22M
Relative Volume:
0.94
Market Cap:
$7.09B
Revenue:
$47.30M
Net Income/Loss:
$-408.73M
P/E Ratio:
-16.23
EPS:
-3.5865
Net Cash Flow:
$-303.86M
1W Performance:
+11.82%
1M Performance:
+22.09%
6M Performance:
+23.78%
1Y Performance:
+63.99%
1-Day Range:
$55.90
$58.75
1-Week Range:
$51.91
$58.75
52-Week Range:
$27.07
$58.75
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
58.20 | 6.73B | 47.30M | -408.73M | -303.86M | -3.5865 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission - Reuters
Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus - Kalkine Media
Scholar Rock advances apitegromab FDA review - grafa.com
Scholar Rock removes Catalent facility from SMA drug application By Investing.com - Investing.com Canada
Scholar Rock is prepared to launch its SMA drug if FDA approves by Sept. 30 - Stock Titan
Eagle Health Investments LP Invests $30.54 Million in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Scholar Rock Holding (SRRK) After Apitegromab Progress Is The Stock Already Fully Valued - Sahm
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab - MarketBeat
How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review - simplywall.st
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks? - Yahoo Finance
Redmile Group (SRRK) updates Scholar Rock stake to 3.6% of common stock - Stock Titan
12 New Hires Receive 51,947 Scholar Rock Equity Awards - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
Scholar Rock (SRRK) Stock Looks Priced At A Premium Today - simplywall.st
SRRK Maintains by JP Morgan -- Price Target Raised to $63.00 - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares - Stock Titan
SRRK Stock Prediction: Huge SMA Drug Launch Breakthrough? (2026 Alert) The Rock (yAPbDwyblt) - Mshale
Scholar Rock at canaccord growth conference: approval path narrows By Investing.com - Investing.com Canada
Scholar Rock at canaccord growth conference: approval path narrows - Investing.com India
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
Q3 EPS Estimates for Scholar Rock Cut by HC Wainwright - MarketBeat
Scholar Rock: Apitegromab's Approval Is Key, Here's My Take Moscow Victory Day Parade (Ok0Q1xN954) - Mshale
Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Potential 15.51% Upside in the Biotech Arena - DirectorsTalk Interviews
Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
SRRK Reiterated by Wedbush -- Maintains Price Target at $58.00 - GuruFocus
Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush - MarketBeat
H.C. Wainwright reiterates Scholar Rock stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Scholar Rock stock rating at buy - Investing.com
SRRK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $65 - GuruFocus
Scholar Rock Holding Corp (SRRK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SRRK Maintained at Buy by Citigroup -- Price Target Raised to $6 - GuruFocus
Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug - marketscreener.com
Vials for an SMA treatment candidate await packaging as FDA review shifts - Stock Titan
Scholar Rock Q2 Earnings Call Highlights - finance.yahoo.com
SRRK SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag -- Update - marketscreener.com
Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates - marketbeat.com
Scholar Rock files $200 million at-the-market offering prospectus with SEC - Investing.com Nigeria
Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlig - GuruFocus
Earnings call transcript: Scholar Rock tops Q2 2026 EPS view, shares rise premarket - Investing.com
Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlights: Dual Paths to FDA Approval ... - Yahoo Finance
Scholar Rock (SRRK) Nears Approval for First Myostatin Inhibitor Amid High Price-to-Sales Valuation - GuruFocus
Is Scholar Rock Holding Corp (SRRK) Positioned for Success After Q2 Earnings Miss? GF Score: 26/100, EPS at -$0.84 - GuruFocus
Form 8K Scholar Rock Holding Corp For: 6 August By Investing.com - Investing.com Nigeria
Scholar Rock Holding Corp 2Q 2026: Net loss $(215.4M), EPS $(1.67) — 10-Q Summary - TradingView
Scholar Rock (NASDAQ: SRRK) details apitegromab review, $492M cash balance - Stock Titan
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):